Video

Dr. Bhat on Emerging Targeted Therapies in CLL

Seema A. Bhat, MD, emerging targeted therapies in chronic lymphocytic leukemia.

Seema A. Bhat, MD, a hematologist specializing in chronic lymphocytic leukemia (CLL) at The Ohio State University Comprehensive Cancer Center–James, discusses emerging targeted therapies in chronic lymphocytic leukemia.

The armamentarium in CLL is expanding, Bhat explains. Currently, the covalently bound BTK inhibitors ibrutinib (Imbruvica) and acalabrutinib (Calquence) are approved. However, patients can develop resistance to these agents over time.

As such, reversible BTK inhibitors, such as LOXO-305 and ARQ 531, are in development, Bhat says.

Zanubrutinib (Brukinsa), which is another covalently bound BTK inhibitor, is also be evaluated in an ongoing head-to-head clinical trial with ibrutinib, Bhat says.

Additionally, the next-generation PI3K inhibitor umbralisib is being evaluated in combination with CD20-directed monoclonal antibodies and other targeted agents, Bhat says. If approved, the agent would add to the current approvals of idelalisib (Zydelig) and duvelisib (Copiktra).

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity